Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
| Website: | www.regulusrx.com |
| Email: | information@regulusrx.com |
| Main Phone: | +1 858 202-6300 |
| Address: | 10614 Science Center Drive |
| Address 2: | Suite 210 |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92121 |
| Exchange: | NSC |
| CEO: | Joseph P. Hagan |
| Employees: | 21 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Regulus Therapeutics is developing treatments for renal, hepatic and central nervous systems diseases based on microRNA targeting.
Regulus Therapeutics (RGLS) is Biopharmaceutical Company that developed drugs that target microRNAs. MicroRNAs are small non-coding RNA that play a role in gene expression.
This fall, presidential candidate Hillary Clinton once again proposed price caps on out-of-pocket payments for pharmaceuticals. Liana Moussatos of Wedbush Securities has followed the price-cap
A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand,
Small-cap companies (that is, companies that are worth between $300 million and $2 billion) can be a risky investment, as smaller companies tend to have lower stock prices and thus are more
Futures Outlook for the Week: 02/4/13This week we are going to cover three C’s: Cocoa, Coffee, and Copper. The first two may be in the market for some counter trend plays and the last of them
LifeLock Inc. (LOCK) began trading as a public company this morning with an initial public offering of 15.7 million shares at $9 each. The $9 per share price tag is below the original price range
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
| Website: | www.regulusrx.com |
| Email: | information@regulusrx.com |
| Main Phone: | +1 858 202-6300 |
| Address: | 10614 Science Center Drive |
| Address 2: | Suite 210 |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92121 |
| Exchange: | NSC |
| CEO: | Joseph P. Hagan |
| Employees: | 21 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Regulus Therapeutics is developing treatments for renal, hepatic and central nervous systems diseases based on microRNA targeting.
Regulus Therapeutics (RGLS) is Biopharmaceutical Company that developed drugs that target microRNAs. MicroRNAs are small non-coding RNA that play a role in gene expression.
This fall, presidential candidate Hillary Clinton once again proposed price caps on out-of-pocket payments for pharmaceuticals. Liana Moussatos of Wedbush Securities has followed the price-cap
A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand,
Small-cap companies (that is, companies that are worth between $300 million and $2 billion) can be a risky investment, as smaller companies tend to have lower stock prices and thus are more
Futures Outlook for the Week: 02/4/13This week we are going to cover three C’s: Cocoa, Coffee, and Copper. The first two may be in the market for some counter trend plays and the last of them
LifeLock Inc. (LOCK) began trading as a public company this morning with an initial public offering of 15.7 million shares at $9 each. The $9 per share price tag is below the original price range
| Last Price 1.04 | Change $ -0.13 | Change % -11.11 | Tick N/A |
| Bid 1.04 | Bid Size 3,000.00 | Ask 1.30 | Ask Size 5,300.00 |
| Open 1.16 | High 1.16 | Low 1.00 | Prev Close 1.17 |
| Last Trade | Volume 294,632 | 52 Wk Hi 1.74 | 52 Wk Low 0.50 |
| Market Cap 21.9 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 21,018,663.00 | EPS (TTM) -1.84 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 1 | 10 |
| Number of Buys | 1 | 10 |
| Number of Sells | 0 | 0 |
| Net Activity | 7695 | 2130745 |
| Last 10 Buys | Shares |
|---|---|
| Timothy Michael Wright | 1,000 |
| William H. Rastetter | 1,000 |
| Joseph P. Hagan | 1,000 |
| Stelios Papadopoulos | 1,000 |
| Daniel R. Chevallard | 1,000 |
| Stelios Papadopoulos | 1,000 |
| Stelios Papadopoulos | 1,000 |
| William H. Rastetter | 1,000 |
| Joseph P. Hagan | 1,000 |
| Mark G. Foletta | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Bruce L.A. Carter | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Kleanthis G. Xanthopoulos | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 3 | 3 | 3 | 3 |
| Low Target Price Estimate | 1 | 1 | 1 | 1 |
| Mean Target Price Estimate | 1.77 | 1.77 | 1.77 | 1.77 |
| Standard Deviation | 0.77 | 0.77 | 0.77 | 0.77 |
| Date of Most Recent Estimate | 05/11/18 | 05/11/18 | 05/11/18 | 05/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.33 | 2.33 | 2.33 | 2.2 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait